# 89bio Inc. (ETNB)

Source: https://www.quantisnow.com/company/ETNB
Generated: 2026-11-17T16:23:42.674Z

- Ticker: ETNB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: 89bio.com

## About

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

## Latest ETNB news and filings

- 2025-11-20 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-89bio-inc-6287846)
- 2025-11-14 21:24 UTC [SEC Form SCHEDULE 13G filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-89bio-inc-6280769)
- 2025-11-13 22:24 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-89bio-inc-6278319)
- 2025-11-10 11:30 UTC [SEC Form 15-12G filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-89bio-inc-6269257)
- 2025-11-03 21:42 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-89bio-inc-6257008)
- 2025-11-03 21:40 UTC [SEC Form 4] [Director Ra Capital Management, L.P. returned 19,889,683 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ra-capital-management-lp-returned-19889683-shares-to-the-6256996)
- 2025-10-31 14:42 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-89bio-inc-6254051)
- 2025-10-31 00:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Laporte Kathleen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-laporte-kathleen-6253374)
- 2025-10-31 00:31 UTC [SEC Form 4] [Director Hayden Michael R closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hayden-michael-r-closing-all-direct-ownership-in-the-6253371)
- 2025-10-31 00:28 UTC [SEC Form 4] [Chief Financial Officer Martins Ryan was granted 35,000 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-martins-ryan-was-granted-35000-shares-closing-6253369)
- 2025-10-31 00:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Altschuler Steven](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-altschuler-steven-6253368)
- 2025-10-31 00:22 UTC [SEC Form 4] [Chief Executive Officer Palekar Rohan was granted 125,000 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-palekar-rohan-was-granted-125000-shares-closing-6253367)
- 2025-10-31 00:22 UTC [SEC Form 4] [Director Mcwherter Charles closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-mcwherter-charles-closing-all-direct-ownership-in-the-company-6253366)
- 2025-10-31 00:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Atkinson Edward Morrow Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-atkinson-edward-morrow-iii-6253364)
- 2025-10-31 00:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Zoth Lota S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-zoth-lota-s-6253363)
- 2025-10-31 00:18 UTC [SEC Form 4] [Officer Le-Nguyen Quoc was granted 50,000 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-le-nguyen-quoc-was-granted-50000-shares-closing-all-direct-6253362)
- 2025-10-31 00:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Babler Martin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-babler-martin-6253360)
- 2025-10-31 00:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Dirocco Derek](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dirocco-derek-6253357)
- 2025-10-31 00:10 UTC [SEC Form 4] [Chief Operating Officer Sarena Francis Willard closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-sarena-francis-willard-closing-all-direct-ownership-6253356)
- 2025-10-31 00:10 UTC [SEC Form 4] [Chief Medical Officer Mansbach Harry H was granted 50,000 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-mansbach-harry-h-was-granted-50000-shares-6253355)
- 2025-10-30 20:47 UTC [SEC Form POSASR filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-89bio-inc-6253060)
- 2025-10-30 20:45 UTC [SEC Form POSASR filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-89bio-inc-6253051)
- 2025-10-30 20:43 UTC [SEC Form POS AM filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-89bio-inc-6253038)
- 2025-10-30 20:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6253029)
- 2025-10-30 20:40 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6253025)
- 2025-10-30 20:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6253015)
- 2025-10-30 20:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6253004)
- 2025-10-30 20:35 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6252998)
- 2025-10-30 20:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6252988)
- 2025-10-30 20:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-89bio-inc-6252975)
- 2025-10-30 16:04 UTC [SEC Form 25-NSE filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-89bio-inc-6251911)
- 2025-10-30 13:03 UTC [SEC Form 8-K] [89bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update](https://www.quantisnow.com/insight/89bio-inc-filed-sec-form-8-k-termination-of-a-material-6251714)
- 2025-10-30 12:58 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-89bio-inc-6251659)
- 2025-10-30 12:47 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-89bio-inc-6251639)
- 2025-10-30 06:00 UTC [Roche purchases shares in tender offer for 89bio, Inc](https://www.quantisnow.com/insight/roche-purchases-shares-in-tender-offer-for-89bio-inc-6250674)
- 2025-10-23 21:10 UTC [SEC Form 4] [Chief Financial Officer Martins Ryan exercised 80,799 shares at a strike of $3.17, increasing direct ownership by 31% to 339,295 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-martins-ryan-exercised-80799-shares-at-a-6243808)
- 2025-10-23 20:40 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-89bio-inc-6243701)
- 2025-10-23 20:01 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-89bio-inc-6243257)
- 2025-10-07 15:57 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-89bio-inc-6225980)
- 2025-10-03 20:01 UTC [SEC Form SCHEDULE 13D filed by 89bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-89bio-inc-6222268)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ETNB
- Earnings history: https://www.quantisnow.com/earnings/ETNB
- Dividend history: https://www.quantisnow.com/dividends/ETNB
- Insider transactions: https://www.quantisnow.com/insiders/ETNB
- Options chain: https://www.quantisnow.com/options/ETNB
- SEC 8-K filings only: https://www.quantisnow.com/company/ETNB/8-k
- RSS and alerts for ETNB: https://www.quantisnow.com/docs/rss-feeds.md
